Dose–response effect of levetiracetam 1000 and 2000 mg/day in partial epilepsy

Boon, Paul; Chauvel, Patrick; Pohlmann‐Eden, Bernd; Otoul, Christian; Wroe, S

doi:10.1016/s0920-1211(01)00323-0

Cited by 85 publications

(71 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The majority of studies (80) did not report whether outcome assessors were blinded to treatment allocation. Twenty studies reported outcome assessors to be blinded and 10 reported that they were unblinded.…”

Section: Were the Outcome Assessors Blinded To The Treatment Allocation?mentioning

confidence: 99%

“…In seven studies, there was no justification for the lack of a washout period. 49,50,80,[83][84][85][86] Five studies, two of which were abstracts, 40,82 failed to provide the information necessary to judge whether this criterion was met. 39,40,69,82,87 4.…”

Section: Did All Participants Have Established Epilepsy With a Constamentioning

confidence: 99%

“…First-phase data from the crossover study 80 were reported in a separate publication 145 and are included in Figure 10. Final crossover data showed that 10 out of 183 participants in the1000 mg/day LEV group, compared with 10 out of 175 in the 2000 mg/day LEV group and two out of 172 in the placebo group, remained seizure free.…”

Section: Summary Statement For Monotherapy Studiesmentioning

confidence: 99%

See 2 more Smart Citations

Clinical effectiveness, tolerability and cost-effectiveness of newer drugs for epilepsy in adults: a systematic review and economic evaluation

Wilby¹,

Kainth²,

Hawkins³

et al. 2005

Health Technol Assess

199

View full text Add to dashboard Cite

Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per monograph and for the rest of the world £3 per monograph.You can order HTA monographs from our Despatch Agents:-fax (with credit card or official purchase order) -post (with credit card or official purchase order or cheque) -phone during office hours (credit card only).Additionally the HTA website allows you either to pay securely by credit card or to print out your order and then post or fax it. NHS libraries can subscribe free of charge. Public libraries can subscribe at a very reduced cost of £100 for each volume (normally comprising 30-40 titles). The commercial subscription rate is £300 per volume. Please see our website for details. Subscriptions can only be purchased for the current or forthcoming volume. Contact details are as follows: Payment methods Paying by chequeIf you pay by cheque, the cheque must be in pounds sterling, made payable to Direct Mail Works Ltd and drawn on a bank with a UK address. Paying by credit cardThe following cards are accepted by phone, fax, post or via the website ordering pages: Delta, Eurocard, Mastercard, Solo, Switch and Visa. We advise against sending credit card details in a plain email. Paying by official purchase orderYou can post or fax these, but they must be from public bodies (i.e. NHS or universities) within the UK. We cannot at present accept purchase orders from commercial companies or from outside the UK. How do I get a copy of HTA on CD?Please use the form on the HTA website (www.hta.ac.uk/htacd.htm). Or contact Direct Mail Works (see contact details above) by email, post, fax or phone. HTA on CD is currently free of charge worldwide.The website also provides information about the HTA Programme and lists the membership of the various committees. HTA NHS R&D HTA ProgrammeT he research findings from the NHS R&D Health Technology Assessment (HTA) Programme directly influence key decision-making bodies such as the National Institute for Clinical Excellence (NICE) and the National Screening Committee (NSC) who rely on HTA outputs to help raise standards of care. HTA findings also help to improve the quality of the service in the NHS indirectly in that they form a key component of the 'National Knowledge Service' that is being developed to improve the evidence of clinical practice throughout the NHS.The HTA Programme was set up in 1993. Its role is to ensure that high-quality research information on the costs, effectiveness and broader impact of health technologies is produced in the most efficient way for those who use, manage and provide care in the NHS. 'Health technologies' are broadly defined to include all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care, rather than settings of care.The HTA programme commissions research only on topics where it has identified key gaps in the evidence needed by the NHS. Suggestions for topics are actively sought from people working in the NHS, the public...

show abstract

Section: Were the Outcome Assessors Blinded To The Treatment Allocation?mentioning

confidence: 99%

Section: Did All Participants Have Established Epilepsy With a Constamentioning

confidence: 99%

Section: Summary Statement For Monotherapy Studiesmentioning

confidence: 99%

See 1 more Smart Citation

Clinical effectiveness, tolerability and cost-effectiveness of newer drugs for epilepsy in adults: a systematic review and economic evaluation

Wilby¹,

Kainth²,

Hawkins³

et al. 2005

Health Technol Assess

199

View full text Add to dashboard Cite

show abstract

“…The results of this trial demonstrated a dose-dependent decrease in seizure frequency with levetiracetam. 25 Larger, open-label studies such as the KEEPER trial and the SKATE trial have further confirmed levetiracetam's efficacy at doses of 1000-3000 mg for partial seizures in adults. Morrell and colleagues conducted an open-label community-based (United States) study of levetiracetam as add-on therapy for partial seizures (KEEPER trial).…”

Section: Use For Adjunct Therapy In Adultsmentioning

confidence: 96%

“…24 Boon and colleagues conducted a continuation trial from the Cereghino and colleagues trial in which a dose-response effect of levetiracetam was evaluated by cross over design (n = 324). 25 Patients with partial seizure were randomized to placebo versus levetiracetam 1000 mg or 2000 mg daily for 16 weeks and were then crossed over to the alternative treatment for 16 weeks. Statistically significant seizure reductions of 16.9% and 18.5% were observed in the 1000 mg and the 2000 mg group versus placebo(p  0.001), respectively.…”

Section: Use For Adjunct Therapy In Adultsmentioning

confidence: 99%

Pharmacotherapy of Epilepsy: Focus on Levetiracetam

Adams

Chung

Eiland

2009

Clinical Medicine. Therapeutics

View full text Add to dashboard Cite

Abstract:Levetiracetam is a second-generation antiepileptic drug which first came to the United States market in 1999. It has a mechanism of action that is not well elucidated. However, it is a very favorable antiepileptic drug due to its reliable pharmacokinetics, minimal drug interactions, seizure efficacy and good tolerability. It is an agent that has established efficacy as an adjunct therapy agent for partial and refractory seizures. As a monotherapy agent, levetiracetam also appears to be an attractive agent with observed efficacy and tolerability. Since levetiracetam has recently become available intravenously, it is also being reviewed as an agent for acute status epilepticus. In pediatrics, levetiracetam is widely used with efficacy seen in small clinical trials for a variety of seizure types. Levetiracetam is well tolerated: the most common adverse effect being somnolence and behavioral effects. Overall, levetiracetam is a notable antiepileptic drug that has added significantly to the current antiepileptic armamentarium.

show abstract

A 24-Year-Old Woman With Intractable Seizures

Schomer

Black²

2008

JAMA

View full text Add to dashboard Cite

Epilepsy, a recurrent seizure disorder affecting 1% of the population, can be genetic in origin and thereby affect multiple members in a family, or it can be sporadic. Many sporadic seizures come from a specific "focus" in the cortex. Focal-onset seizures account for 60% of all cases of epilepsy. Among patients with partial seizures, 35% respond poorly to available medication and may benefit from neurosurgical excisional surgery. In cases in which epilepsy is localized through different modes (electroencephalogram, magnetic resonance imaging, etc) to a specific area of the brain where there is an associated lesion, more than half of patients can expect a successful surgical outcome. In patients with consistent seizure-associated behavior but without a lesion, surgical treatment is less successful. Ms H, a young woman with a history of medically intractable partial epilepsy, does not have an anatomical lesion but wants to know if a surgical approach is a good option for her.

show abstract

Dose–response effect of levetiracetam 1000 and 2000 mg/day in partial epilepsy

Cited by 85 publications

References 10 publications

Clinical effectiveness, tolerability and cost-effectiveness of newer drugs for epilepsy in adults: a systematic review and economic evaluation

Clinical effectiveness, tolerability and cost-effectiveness of newer drugs for epilepsy in adults: a systematic review and economic evaluation

Pharmacotherapy of Epilepsy: Focus on Levetiracetam

A 24-Year-Old Woman With Intractable Seizures

Contact Info

Product

Resources

About